Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

Softer volume environment triggers downgrade

Seek
3:27pm
February 13, 2024
SEK’s 1H24 result was a miss versus consensus on most key headline metrics. Whilst the downgrade to FY24 guidance was disappointing, and saw the stock trade down ~5% on the day, we note a key driver of the downgrade was the continuation of the seasonally softer volume environment into early 2H24. We lower our FY24F-FY26 EBITDA by ~2-6% on the result and change to guidance. Our DCF-derived valuation is lowered to A$27.30 (from A$27.80) with near term downgrades offset to a degree by less conservatism in our outer year margin assumptions. Add maintained.

1H24 result: Are we there yet?

Vulcan Steel
3:27pm
February 13, 2024
VSL is a cyclical business, which we believe is close to its earnings nadir. As largely expected, the 1H24 result was weak, with revenue slowing further in the final two months of 1H24. However, commentary was incrementally more positive, with sales activity showing early signs of stabilising and increased customer inquiry levels in certain segments throughout Jan/Feb-24. Our investment thesis has never been about FY24 earnings, rather we believe that through the cycle VSL is a low double digit PER business, with the upside really an earnings story in FY25/26/27 – resurgent demand restoring historical volumes and prices. To this end, our thesis centres on buying cyclical companies on high PERs at their earnings nadir, an investment thesis which remains largely unchanged despite our forecast for a weaker than expected 2H24 earnings contribution. Add rating retained, with an A$8.60/sh target price (previously $9.00/sh).

1H24: UHF reaches first close

HealthCo REIT
3:27pm
February 13, 2024
1H24 saw the Healthscope private hospital transaction further bedded down alongside the Unlisted Healthcare Fund which added four institutional investors in addition to HCW ($1.3bn first close with $650m in total equity commitments). The focus now turns to unlocking the development pipeline. Portfolio metrics remain stable (cash collection 100%; occupancy 99%; and WALE +12 years). Asset recycling has been a focus with further asset sales targeted in 2H24. Current gearing 34%. NTA $1.65. FY24 guidance comprising FFO and DPS of 8cps was reaffirmed. Retain Add with a revised $1.61 price target.

1H24 earnings: Tolerate It

BRG Group
3:27pm
February 13, 2024
BRG exceeded market expectations for EBIT in the first half of FY24 and provided guidance for the full year that was within the range of consensus forecasts. So why did the shares fall 8.5%, erasing all their gains from the past two months? It was all about revenue, which came in below expectations, raising questions about the strength of consumer demand. This, we think, is too simplistic. Gross margins were much higher than forecast, which says to us that BRG has not followed its competitors down the path of heavy discounting to stimulate sales. Instead it has sought to manage its business to the delivery of profit and to maintain its customer’s perception of product value. We have trimmed our full year numbers, but really not by much. We think BRG will continue to manage costs and new product development to achieve steady growth in earnings. In isolation, we think the share price reaction was overly negative today, but we still can’t bring ourselves to see current multiples as an appealing entry point. We like BRG for the long-term, but it’s not cheap enough for us for chase it until it’s below $23. For now, Hold.

1H broadly in line; Behring GPM up, Seqirus/Vifor soft

CSL Ltd
3:27pm
February 13, 2024
1H results were broadly in line, with double-digit underlying top and bottom line growth and strong OCF. Divisional sales were mixed, with strong plasma collections propelling Behring sales (+14%), while Seqirus was soft (+2%), but above reduced market immunisation rates, and Vifor headwinds expected to “dampened” near-term growth prospects. Notably, Behring GPM expanded above expectations (+230bp, 50%), owing to a DD decline in cost/litre and numerous other initiatives, with ongoing gains expected to continue supporting the return to pre-COVID margins (c58%) still targeting 3-5 years. FY24 guidance (ccNPATA +13-17%) was reaffirmed, implying a solid 2H (+17% at mid-point), despite Seqirus unfavourable seasonality and lower near-term Vifor growth, with double-digit earnings growth over the medium term also reiterated. Our PT move to A$315.35 on CSL112 removal and modest earnings changes. Add.

Increasing ROE and Accenture partnership impress

Challenger Financial Svcs
3:27pm
February 13, 2024
CGF’s 1H24 normalised NPAT of A$201m was 1% above consensus (A$200m) and +20% on the pcp. Overall, we saw this as a positive result owing to factors including: strong ROE expansion; a solid cost-to-income performance; and the announcement of a value-add IT transformation program. We lift our CGF FY24F/FY25F EPS by 3%-6% reflecting an increase in our life COE margin assumptions, and the cost-out savings from the IT transformation program. Our PT rises to A$7.80. ADD maintained.

Getting in to water-out

Reliance Worldwide
3:27pm
February 13, 2024
RWC has announced the acquisition of Holman Industries in Australia for $160m. We think the deal looks reasonable from both a financial and strategic perspective with Holman marking RWC’s first foray into the ‘water-out’ market, complementing the company’s existing presence in the ‘water-in’ market in Australia. Given management has stated the water-out market is a strategic priority in each of RWC’s three regions (Americas, EMEA, APAC), we think further acquisitions in this space are likely in the future. We increase FY24/25/26F underlying EBITDA by 1%/6%/7% after factoring in the Holman acquisition. We make no changes to existing baseline assumptions. Our target price rises to $4.20 (from $3.56) reflecting a roll-forward of our model to FY25 forecasts. We also increase our PE-based valuation multiple slightly to 15x (from 14x) on an improving medium-term outlook reflecting a stabilisation in the interest rate environment (with the potential for interest rate cuts). RWC is due to report its 1H24 result on 19 February.

In a hot spot

Clarity Pharmaceuticals
3:27pm
February 13, 2024
Clarity Pharmaceuticals (CU6) is a clinical stage radiopharmaceutical company developing products for use in prostate cancer, neuroblastomas, and neuroendocrine tumours. CU6’s key clinical assets are Targeted Copper Theranostics (TCT) which pairs copper isotopes to bind and aggregate around specific tumours. These light up under PET imaging (diagnostic) and have the potential to deliver therapeutic anti-tumour payloads. The company is undertaking seven clinical trials (three theranostic and four diagnostic trials in progress), including a Phase 3 trial for its prostate cancer diagnostic expected to conclude in CY25. Interest is high in the space with significant M&A activity. Coupled with several key catalysts expected to read out over the next 24 months, CU6 has emerged as a stock to watch.

The need to get leaner (again)

Beach Energy
3:27pm
February 12, 2024
BPT posted a softer 1H24 result, with underlying EBITDA (-8%) and NPAT (-26%) trailing Visible Alpha consensus estimates. Although it was clear costs were partly driven by temporary factors. New BPT management announced a strategic review into its cost performance, flagging that the largest challenge sits in its offshore operations. Waitsia first gas is expected in mid CY24. We see potential for BPT to regain significant earnings power if it can deliver Waitsia, but at current it looks close to fair value. Maintain Hold rating.

Offshore to be a key driver, not just a passenger

Car Group
3:27pm
February 12, 2024
CAR’s 1H24 result was broadly a strong result overall, in our view, with double-digit proforma revenue and EBITDA growth across all operating regions a key takeaway. On an adjusted basis, the result was ~1-2% beat vs consensus at the EBITDA (A$277m, +19% proforma on pcp) and Adj. NPAT line (A$163m, +34% on pcp). We increase our FY24F-FY26F EBITDA by ~4-5% (details below). Our DCF-derived valuation and TP increases to A$32.20 (from A$28.10). Hold maintained.

News & Insights

The Your Wealth publication is our half yearly scrutiny into current affairs for wealth management. Our latest Issue 29 is out now.

The second half of 2025 will be an interesting time for everyone. Geopolitical uncertainty prevails. How will all of this impact the Australian investor and in particular, their wealth and retirement savings? Whether you are an accumulator, saving for short- and long-term goals, or a retiree, hoping for a comfortable retirement, the ability to manage this uncertainty will be key.

When we published the previous Your Wealth – First Half 2025, the Division 296 Bill (Div296) was also facing uncertainty. The Bill was eventually blocked in the Senate prior to the Federal Election. The Labor Party succeeded in winning so it’s Ground Hog Day for Div296. The Government doesn’t have the numbers in the Senate to pass the Bill without support from other parties. The Greens are the likely negotiating party but will undoubtably have their own agenda. Regardless, there is a high probability this legislation will be passed once Parliament resumes.

Our message to our clients is to wait until we know more details and to not act in haste.

In addition to our Feature Article which provides further insights on Div296, this edition also Spotlights the Aged Care changes due this year, with the start date pushed back to 1 November.

We hope readers enjoy this edition of Your Wealth.


Morgans clients receive exclusive insights such as access to our latest Your Wealth publication. Contact us today to begin your journey with Morgans.

      
Contact us
      
Read more
Michael Knox, Chief Economist, reveals how the OECD and RBA’s outdated assumptions about global trade fail to account for China’s Marxist-Leninist economic strategies.

This morning, I was asked to discuss Sarah Hunter’s presentation from yesterday. Sarah, the Assistant Governor and Chief Economist at the Reserve Bank of Australia (RBA), delivered a detailed and competent discussion on the conventional view of tariffs’ impact on the international economy. She highlighted that tariffs typically increase inflation and reduce economic output, a perspective echoed by the OECD in a similar presentation overnight. Sarah’s analysis focused on the potential shocks tariffs could cause, particularly their effects on GDP and inflation.

Drawing on my experience as an Australian trade commissioner and my work in Australian embassies, I found her presentation particularly interesting. My background allowed me to bring specialist knowledge to the conversation, which I believe gave me an edge. Notably, I observed that the RBA seems to lack analysts closely tracking individual policymakers in the Trump administration, such as Scott Bessent, whose views on tariffs and competition differ from the general assumptions. The conventional view assumes a world of perfectly competitive countries adhering to international trade rules and unlikely to engage in conflict—a scenario that doesn’t align with the current global trade environment, especially between China and the United States.

China, operating as a Marxist-Leninist economy, aims to dominate global markets by building monopolies in areas like rare earths, nickel, copper, and other base metals. It maintains a managed exchange rate, despite promises to the International Monetary Fund for a freely floating currency. If China allowed its currency, the RMB, to float, it would likely appreciate significantly, increasing imports and reducing its trade surplus. This would create a more balanced international trade environment, potentially reducing the need for other countries to impose tariffs. However, major institutions like the OECD and RBA seem to misjudge the nature of this trade shock, relying on outdated assumptions about global trade dynamics.

The international community also appears to overlook specific U.S. policy intentions, such as those articulated by figures like Peter Navarro and Scott Bessent. The U.S. aims to use tariffs selectively to bolster industries like pharmaceuticals, precision manufacturing, and motor vehicles. This misunderstanding leads public institutions to perceive unspecified risks, as reflected in Sarah’s otherwise able presentation. Because the RBA and similar institutions view the world as fraught with undefined risks, they are inclined to keep interest rates low, responding to perceived threats rather than an equilibrium model.

Interestingly, data from the U.S. economy contradicts the expected negative impacts of tariffs. The Chicago Fed National Activity Indicator, a reliable gauge of economic growth since the 2008 financial crisis, shows U.S. growth above the long-term trend for the first four months of this year. This suggests resilience despite tariff-related shocks. Ideally, growth will slow later this year, prompting the Federal Reserve to cut rates, facilitating a soft landing and a decline in the U.S. dollar to boost global commodity prices. However, this nuanced outlook wasn’t evident in yesterday’s presentation.

Moreover, the anticipated rise in U.S. inflation due to tariffs isn’t materialising. Scott Bessent recently noted that U.S. CPI inflation is lower than expected, with core inflation shown as the (16% trimmed mean) at 3% for the past two months . Core inflation  excluding  food and energy CPI  is only at 2.8%. This suggests that Chinese suppliers are absorbing tariff costs to maintain market share, rather than passing them on as higher prices. Recent Chinese data supports this, showing a slight decline in manufacturing confidence and coal consumption, indicating reduced factory output and electricity use. This points to a modest slowdown in China’s economy. So far the expected negative effects on U.S. prices and output are not occurring.

In summary, the fears expressed by institutions like the RBA and OECD about the Trump administration’s trade policies appear overstated. The U.S. economy is not experiencing the predicted declines in output or increases in inflation. While these effects may emerge later, the current data suggests that the risks are not as severe as anticipated, highlighting a disconnect between theoretical models and real-world outcomes.

Read more
Michael Knox outlines the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and his own analysis for Australia.

Today, I’m presenting the first page of my updated presentation, which focuses on GDP growth and inflation expectations for major economies. Before diving into that, I want to clarify a point about U.S. trade negotiations that has confused some media outlets.

In the previous Trump Administration ,there was single trade negotiator, Robert Lighthizer, held a cabinet position with the rank of Ambassador. This time, to expedite negotiations and give them more weight, Trump has appointed two additional cabinet-level officials to handle trade talks with different regions. For Asian economies, Scott Bessent and Ambassador Jamison Greer, who succeeded Lighthizer and previously served on the White House staff, are managing negotiations, including those with China. For Europe, Howard Lutnick, the Commerce Secretary, and Ambassador Greer are negotiating with the European Trade Representative. When the EU representative visits Washington, D.C., they meet with Lutnick and Greer, while Chinese or Japanese representatives engage with Bessent and Greer.

In my presentation today, I’m outlining the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and my own analysis for Australia.

For the U.S., the best-case scenario is a soft landing, with growth slowing but remaining positive at 1.3% this year and rising to 1.7% next year. This slowdown allows the Federal Reserve to continue cutting interest rates, leading to a decline in the U.S. dollar. This in turn ,triggers a recovery in commodity prices. These prices have stabilized and are now trending upward, with an expected acceleration as the dollar weakens.

U.S. headline inflation is projected to be just below 3% next year, with higher figures this year driven by tariff effects.



Global Economic Perspective

In the Euro area, growth is accelerating slightly, from just under 1% this year to 1.2% next year, with inflation expected to hit the 2% target this year and dip to 1.9% next year.

China’s GDP growth is forecast  at 4% for both this year and next, a step down from previous 5% rates, reflecting a significant slump in domestic demand and very low inflation  Chinese Inflation is only  :   0.2% last year, 0.4% this year, and 0.9% next year.  Despite a massive fiscal push, with a budget deficit around 8% of GDP, China’s debt-to-GDP ratio is rising faster than the U.S.. Yet this is  yielding more modest  domestic growth.

India, on the other hand, continues to outperform, with 6.5% GDP growth last year, 6.2% this year, and  6.3%  next year, surpassing earlier projections.

Read more